STOCK TITAN

InMed Pharmaceuticals Inc. Common Shares - INM STOCK NEWS

Welcome to our dedicated page for InMed Pharmaceuticals Common Shares news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on InMed Pharmaceuticals Common Shares stock.

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a leading Canadian clinical-stage biopharmaceutical company at the forefront of cannabinoid research and development. Specializing in the creation of novel therapies, InMed harnesses the extensive pharmacology of cannabinoids, combined with cutting-edge drug delivery systems.

InMed's innovative approach includes a robust product pipeline featuring:

  • INM-755: A topical cream for the treatment of epidermolysis bullosa, a rare skin condition.
  • INM-088: An ophthalmic formulation targeting glaucoma to preserve retinal function.
  • INM-901: A promising treatment for Alzheimer's disease, showing multiple mechanisms of action to improve cognitive and memory functions.
  • INM-089: Aimed at treating age-related macular degeneration (AMD), focusing on retinal protection and functionality.

The company's proprietary IntegraSyn manufacturing system ensures the production of high-quality pharmaceutical-grade cannabinoids, positioning them as a key player in the industry.

InMed's recent achievements include:

  • Completion of a Phase 2 clinical trial for INM-755.
  • Initiation of two new preclinical programs for Alzheimer's and AMD.
  • Strong financial performance with significant revenue growth from its subsidiary BayMedica, which supplies rare cannabinoids to the health and wellness sector.

InMed's commitment to advancing cannabinoid science is evident through its strategic partnerships, rigorous research, and innovative product development, making significant strides in treating diseases with high unmet medical needs. For more information, visit www.inmedpharma.com.

Rhea-AI Summary

InMed Pharmaceuticals Inc. (Nasdaq: INM) will be represented by President and CEO Eric A. Adams and SVP of Preclinical Research and Development Eric Hsu during a webinar event titled "Exploring the Neuroprotective Qualities of Rare Cannabinoids". The event is scheduled for November 17, 2022, starting at 8:30 am Pacific/11:30 am Eastern. Interested participants can register for the complimentary event at Tribe Public's website. InMed focuses on researching and developing rare cannabinoids for various medical applications, addressing high unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.3%
Tags
none
-
Rhea-AI Summary

InMed Pharmaceuticals (Nasdaq: INM) announces support for Epidermolysis Bullosa (EB) Global Awareness Week from October 25-31, 2022. The company aims to raise awareness about EB, a rare genetic skin disorder characterized by fragile skin and blisters. Senior VP Alexandra Mancini emphasized the importance of the disease and the company's Phase 2 study on a cannabinol cream for symptom relief. InMed will share educational content and personal stories via social media during this week, collaborating with organizations like DEBRA to support the EB community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.12%
Tags
none
-
Rhea-AI Summary

InMed Pharmaceuticals (Nasdaq: INM) reported financial results for the fiscal year ending June 30, 2022, revealing a net loss of $18.6 million, up from $10.2 million the previous year. Research and development expenses rose to $7.3 million from $5.3 million, driven by increased clinical activities. The company has initiated a Phase 2 clinical trial for INM-755, targeting epidermolysis bullosa, with nine patients enrolled so far. Following a strategic realignment, InMed will focus on its pharmaceutical drug development while scaling back on its BayMedica subsidiary.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.51%
Tags
Rhea-AI Summary

InMed Pharmaceuticals Inc. (Nasdaq: INM) will release its financial results for the fiscal year ending June 30, 2022, on September 23, 2022. The company specializes in rare cannabinoids and aims to address diseases with unmet medical needs through its clinical programs. A conference call and webcast will be held at 10:00 AM PT on the same day. Participants are encouraged to register in advance to receive dial-in details. Financial statements will be available on their official website and SEDAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
conferences earnings
-
Rhea-AI Summary

InMed Pharmaceuticals announced the closing of a private placement of 691,245 common shares at $8.68 each, raising about $6 million. The funds will support pipeline development, enhance manufacturing capabilities, and bolster intellectual property efforts. Investors also received options to purchase up to 1,382,490 additional shares at $8.44 each, valid for seven years. This placement, arranged by H.C. Wainwright & Co., is exclusively for accredited investors under SEC regulations. The securities will not be offered in the U.S. until registered or exempt from registration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.86%
Tags
none
-
Rhea-AI Summary

On September 9, 2022, InMed Pharmaceuticals (Nasdaq: INM) announced a securities purchase agreement with institutional investors for the sale of 691,245 common shares at $8.68 per share, aiming to raise approximately $6 million. The offering is expected to close on or about September 13, 2022. The proceeds will fund pipeline development, manufacturing, and intellectual property initiatives. Additionally, the company will issue unregistered preferred investment options for up to 1,382,490 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
70.42%
Tags
none
Rhea-AI Summary

InMed Pharmaceuticals Inc. (Nasdaq: INM) announced updates on its research and development efforts, including plans to complete enrollment in a Phase 2 clinical trial for epidermolysis bullosa by year-end. Despite enthusiasm for its cannabinoid analog program following the BayMedica acquisition, market demand for BayMedica's products in the Health & Wellness sector has declined, leading to uncertainty in revenues and an expected non-cash impairment charge of approximately $3.5 million. The company plans to refocus on its pharmaceutical drug development, reducing its exposure to the H&W market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
Rhea-AI Summary

InMed Pharmaceuticals Inc. (Nasdaq: INM) announced a consolidation of its share capital, reducing the number of outstanding shares from approximately 18 million to 720,597 on a 1-for-25 basis. This move aims to regain compliance with Nasdaq's continued listing requirements. The consolidation will not change the ownership percentage for shareholders. Trading of the post-consolidation shares will commence on September 7, 2022, with the trading symbol 'INM' and a new CUSIP number. Registered shareholders will receive instructions via mail, and no fractional shares will be issued.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.9%
Tags
none
-
Rhea-AI Summary

InMed Pharmaceuticals (Nasdaq: INM) has appointed Nicole Lemerond to its Board of Directors, enhancing its financial and healthcare expertise. Lemerond, a seasoned financial executive with over 25 years of experience, takes over from Adam Cutler, who stepped down after serving since 2015. The transition aims to bolster InMed's strategic initiatives as it continues to lead in the research and commercialization of rare cannabinoids. This change is expected to strengthen management and contribute to value creation for stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
management
Rhea-AI Summary

InMed Pharmaceuticals (Nasdaq: INM) announced key developments in its Phase 2 clinical trial for INM-755 cannabinol cream targeting epidermolysis bullosa (EB). The trial has expanded to include adolescents aged 12-17 after safety data review, with the first adolescent patient successfully enrolled and treated. Additionally, a patent for CBN's use in EB treatment has been granted in Japan, enhancing InMed's intellectual property portfolio. Currently, eight clinical trial sites across Europe are activated, with two more expected soon, aiming for 20 enrolled patients by the end of 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.99%
Tags

FAQ

What is the current stock price of InMed Pharmaceuticals Common Shares (INM)?

The current stock price of InMed Pharmaceuticals Common Shares (INM) is $4.66 as of December 24, 2024.

What is the market cap of InMed Pharmaceuticals Common Shares (INM)?

The market cap of InMed Pharmaceuticals Common Shares (INM) is approximately 3.3M.

What is InMed Pharmaceuticals Inc.?

InMed Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company specializing in the research, development, and manufacturing of novel cannabinoid-based therapies.

What products are in InMed's pipeline?

InMed's product pipeline includes INM-755 for epidermolysis bullosa, INM-088 for glaucoma, INM-901 for Alzheimer's disease, and INM-089 for age-related macular degeneration.

What is the IntegraSyn manufacturing system?

IntegraSyn is InMed's proprietary manufacturing system designed to produce high-quality pharmaceutical-grade cannabinoids efficiently.

What recent achievements has InMed made?

Recent achievements include completing a Phase 2 clinical trial for INM-755, launching preclinical programs for Alzheimer's and AMD, and significant revenue growth from BayMedica.

Who are InMed's strategic partners?

InMed collaborates with various pharmaceutical and biotechnology companies to advance its cannabinoid research and development efforts.

What financial outlook does InMed have?

InMed has shown strong financial performance, with revenue growth from its subsidiary BayMedica and a solid cash position to support its ongoing operations.

What diseases does InMed target?

InMed targets diseases with high unmet medical needs, including epidermolysis bullosa, glaucoma, Alzheimer's disease, and age-related macular degeneration.

How does InMed contribute to the health and wellness industry?

Through its subsidiary BayMedica, InMed supplies rare cannabinoids to brands within the health and wellness industry, driving revenue growth and expanding market reach.

Where can I find more information about InMed?

For more information, visit InMed's websites at www.inmedpharma.com and www.baymedica.com.

What are the future plans for InMed's product development?

InMed plans to further develop its proprietary small molecule drug candidates, continue preclinical and clinical trials, and explore new therapeutic areas.

InMed Pharmaceuticals Inc. Common Shares

Nasdaq:INM

INM Rankings

INM Stock Data

3.35M
720.04k
0.87%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
VANCOUVER